• HOME
  • SIGN UP
  • LOGIN
  • KALC

대한폐암학회

D-104 Today 2026-07-29

  • SIGN UP
  • LOGIN
  • KALC 2026
    • Invitation
    • Overview
    • Committee
    • Venue
    • News & Notice
    • Past KALC
  • PROGRAM
    • Program at a Glance
    • Scientific Program
    • E-poster
    • Invited Faculty
  • SUBMISSION
    • Abstract Submission
    • Presentation Guidelines
    • Awards
  • ATTENDANCE
    • Registration
    • Transportation
    • Accommodation
    • More about Seoul
    • Visa
  • SPONSORSHIP
    • Sponsorship Opportunities
    • Our Sponsors

D-104 Today 2026-07-29

KALC 2025 INTERNATIONAL CONFERENCE NOVEMBER 7THU ~ 8FRI, 2025 LOTTE HOTEL WORLD, SEOUL, KOREA

HOME
  • KALC 2026
    • KALC 2026
    • PROGRAM
    • SUBMISSION
    • ATTENDANCE
    • SPONSORSHIP
    • SIGN UP
  • News & Notice
    • Invitation
    • Overview
    • Committee
    • Venue
    • News & Notice
    • Past KALC
  • Invitation
  • Overview
  • Committee
  • Venue
  • News & Notice
  • Past KALC

News & Notice

[KALC 2026 Vol.10] 사전등록 마감까지 11일! 다양한 경품 이벤트도 함께 만나보세요.
Writer KALC 2026 Date 2026-07-27 Hits 16

 

 

Next [KALC 2026 Vol.10] 11 Days Left for Regular Registration! Join Our Exciting Prize Events 2026.07.27
Previous [KALC 2026 Vol.9-2] Early-bird Registration Ends Tomorrow! Register Now! 2026.07.16
List

Korean Association for Lung Cancer

#1322, Rosedale Officetel, 280, Gwangpyeong-ro, Gangnam-gu, Seoul, 06367, Korea

E-mail. kalc@lungca.or.kr  Tel. +82-2-741-8540

KALC IC 2026 Secretariat

Program & Abstract

E-mail. scientific.kalcic@lungca.or.kr  T. +82-2-6411-7372

General & Registration

E-mail. kalcic@lungca.or.kr   T. +82-2-6411-7378(General), 7319(Registration)

Copyright © Korean Association for Lung Cancer. All Rights Reserved.

사전등록 양식을 작성하는 모습

26년도 대한폐암학회 연회비를 납부하셔야 회원가로 등록이 가능합니다. 연회비 납부하시겠습니까?

회비 납부하기 비회원으로 등록하기

Session IV (A)
Oral Presentation 1

  • September 10 (Thu), 14:45-15:45
  • Room A (Crystal Ballroom 3, 3F)
Oral Present
Abstract No. Presentation Time Abstract Title Presenter Name Affiliation Country
A-0047 14:45-14:55 Lung Cancer Screening in Korean Women Who Have Never Smoked with a Family History of Lung Cancer: The NIKE Study So Yeon (lydia) Kim Samsung Medical Center Korea
A-0106 14:55-15:05 Beyond Solid Size: Favorable Prognostic Value of Ground-Glass Opacity in Stage IA Lung Adenocarcinoma Sung Goo Park Samsung Medical Center Korea
A-0212 15:05-15:15 Cardio-Oncology Clinic Involvement and Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Receiving Targeted Therapy Hyukjin Park Chonnam National Univ. Korea
A-0183 15:15-15:25 Real-World Outcomes of Neoadjuvant Immunotherapy versus Definitive Chemoradiotherapy with Durvalumab Consolidation in Stage III Non-Small Cell Lung Cancer Hye In Lee Seoul National Univ. Korea
A-0091 15:25-15:35 Interim Analysis of Camrelizumab Plus Pemetrexed and Carboplatin in Advanced Non-Squamous NSCLC Juwhan Choi Korea Univ. Korea
A-0017 15:35-15:45 Autologous Vax-NK Consolidation Therapy in ES-SCLC: Identification of Predictive Biomarkers via High-Dimensional Circulating Immune Cell Profiling Sung-Woo Lee Chonnam National Univ. Korea

Session V (A)
Oral Presentation 2

  • September 10 (Fri), 09:10-10:10
  • Room A (Crystal Ballroom 3, 3F)
Oral Present
Abstract No. Presentation Time Abstract Title Presenter Name Affiliation Country
A-0207 09:10-09:20 Patient-Specific Lung Cancer Tumoroids for Studying Tumor-Stroma-Immune Interactions and Personalized Immuno-Oncology Yoo Ri Ko Asan Medical Center Korea
A-0118 09:20-09:30 Unbiased Transcriptome-Derived AI Classification of Tertiary Lymphoid Structures on H&E Images Predicts Survival and Immune Microenvironment in NSCLC Jaeyoon Lee Northwestern Univ. Korea
A-0097 09:30-09:40 Prognostic Impact of Spread Through Air Spaces and Optimal Surgical Extent in Stage I NSCLC after Sublobar Resection Sangil Yun Seoul National Univ. Korea
A-0134 09:40-09:50 Phenotype-Dependent Nonlinear Associations Between Tumor Size and Aggressive Histologic Features in Lung Adenocarcinoma Hyojin Kim Seoul National Univ. Korea
A-0100 09:50-10:00 Beyond Major Pathological Response: Favorable Pathological Response Improves Risk Stratification After Neoadjuvant Chemoimmunotherapy for Resectable NSCLC Hsiang Teng Tri-Service General Hospital Taiwan
A-0057 10:00-10:10 Pathologic Response in Lymph Nodes after Neoadjuvant Therapy in NSCLC: Tumor Bed Extent, Not VT%, Drives Survival Associations Sungjin Kim Seoul National Univ. Korea

Basic & Translational Research / Biology / Pathology

Basic & Translational Research / Biology / Pathology
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0033 PE1-01 Designing Novel Therapy for Lung Cancer using Monobody Scaffolds Targeting EGFR Tushar Kushwaha All India Institute Of Medical Sciences India
A-0056 PE1-02 Mutational Profiling and Network Analysis of Circulating Cell-Free DNA in Chemical Carcinogen-Induced Murine Lung Cancer Models Saumya Patel Gujarat University India
A-0088 PE1-03 Optimizing Intraoperative STAS Prediction in Stage IA Lung Adenocarcinoma: Composite Rule Integrating Frozen and CT Findings Yeon Bi Han Seoul National University Bundang Hospital Korea
A-0132 PE1-04 Inflammation Meets Matrix Remodeling: NF-kB and MMP-3 Signatures in COPD-Associated Lung Carcinogenesis Isura Febrihartati Faculty Of Medicine, University Of Lampung Indonesia
A-0028 PE1-05 DNA Methylation Evaluation in Blood-Derived Cell-Free DNA as an Approach to Identify Biomarkers for the Early-Stage Lung Cancer Diagnosis Deep Raj Yadav King George's Medical University India
A-0063 PE1-06 Translational Evaluation of 2 beta-Hydroxybetulinic Acid 3-Oleiate Against EGFR/KRAS-Driven Redox-Metabolic Vulnerabilities in Non-Small Cell Lung Cancer Danish Ahmed Sam Higginbottom University Of Agriculture, Technology And Sciences India
A-0060 PE1-07 Restoring Mitochondrial Apoptosis in Non-Small Cell Lung Cancer Through Pharmacoinformatic Modulation of the STAT3/MCL-1 Axis Rizki Rachmad Saputra Universitas Palangka Raya Indonesia
A-0067 PE1-08 Transcriptomic Analysis of Glycyrrhiza glabra (Licorice) Derived microRNAs and Their Cross-Kingdom Regulatory Potential in Lung Carcinoma Mitsu Patel Gujarat University India
A-0074 PE1-09 Aloesin inhibits lung cancer metastasis, apoptosis and proliferation by modulating the JAK/STAT3 signaling pathway N Singh Csvtu, Bhilai India
A-0073 PE1-10 Curcumin-Loaded Hybrid Polymeric Nanoparticles Inhibit Diethylnitrosamine (DEN) and 2-acetylaminofluorene -Induced Lung Carcinogenesis via Modulation of EGFR and Apoptosis Deepika Singh Shuats India
A-0071 PE1-11 Revesterol encapsulated Solid Lipid Nanoparticles Inhibit the Diethylnitrosamine/2-Acetylaminofluorene Induced Lung Cancer by modulating Apoptosis and Suppressing Proliferation Deepika Singh Shuats India
A-0069 PE1-12 Application of Machine Learning and Artificial Intelligence for Prediction of Lung Cancer Risk in Central India Manvendra Singh Hmfa Miet India
A-0078 PE1-13 Efficacy Evaluation of Circulating Tumor Cells Enrichment Platforms in Advanced Lung Cancer: A Pilot Study Jae Heun Chung Pusan National University Yangsan Hospital Korea
A-0081 PE1-14 Development of an Orthotopic Mouse Model for Spread Through Air Space in EGFR E19del NSCLC with Gefitinib Resistance Sungjin Kim Seoul National University Bundang Hospital Korea
A-0144 PE1-15 Engineered PterostilbeneChitosan Nanoparticles Combat Benzopyrene-Induced Lung Cancer through Alteration of HO-1/Nrf2 Signaling Pathway D Chauhan Rajkamal Science & Management College India
A-0140 PE1-16 Umbelliferone-Chitosan nanobeads ameliorate Diethylnitrosamine induced Lung Carcinogenesis in rats via alteration of Nrf-2/HO-1 and PI3K/AKT/NF-B signaling pathway V Kumar Shalom Institute Of Health & Allied Sciences India
A-0128 PE1-17 Ganoderic Acid-Chitosan Lipid Nanoparticles Attenuate Benzopyrene-Induced Lung Cancer via Alteration of PI3K/Akt/mTOR, NF-B and MAPK/ERK Signaling Pathway Vikas Kumar Sam Higginbottom University Of Agriculture, Technology & Sciences India
A-0127 PE1-18 Clinicopathologic correlates of TTF-1 expression pattern in differentiated lung adenocarcinoma Heae Surng Park Ewha Womans University Medical Center Korea
A-0125 PE1-19 Transcriptomic Deconvolution of Non-Small Cell Lung Cancer Resection Margins Identifies a 5-Gene Signature Predicting Post-Lobectomy Recurrence Hafsa Riaz Islamic University Of Indonesia Pakistan
A-0123 PE1-20 Patient-Derived Organoids Reveal Tumor Heterogeneity and Plasticity Underlying Drug Resistance in Lung Squamous Cell Carcinoma Ji Eun Park Gwangju Institute of Science and Technology Korea
A-0122 PE1-21 Comparative Analysis of Bronchoalveolar Lavage Fluid-Derived Exosomal microRNA Profiles between Early-Stage and Advanced-Stage Non-Small Cell Lung Cancer Hyerin Kang Dongtan Sacred Heart Hospital Korea
A-0165 PE1-22 Coexisting ALK Rearrangement, EGFR L858R Mutation, and Germline BRIP1 Variant in Lung Adenocarcinoma With Durable Response to Alectinib Priscillia Imelda Dharmais Cancer Hospital, National Cancer Center, Indonesia Indonesia
A-0163 PE1-23 Claudin 18.2 as a Specific Diagnostic Marker for Pulmonary Invasive Mucinous Adenocarcinoma Jungsup Byun Daegu Fatima Hospital Korea
A-0167 PE1-24 Targeting the PARP1/SRC Axis Associated with DNA Repair and Metastatic Progression in NSCLC: Pharmacoinformatic Study of Xylaria sp. Metabolites Rizki Rachmad Saputra Universitas Palangka Raya Indonesia
A-0174 PE1-25 Quercetin and Vitexin as Multi-Target Inhibitors of KRAS, ALK, and BRAF in NSCLC Kajal Arora Galgotias University India
A-0179 PE1-26 Integrated Bioinformatics Analysis For Identification Of Key Metabolic Hub Genes In Lung Cancer Sahil Arora Sharda University India
A-0192 PE1-27 Platelet Indices as Prognostic Biomarkers in Lung Cancer: An Updated Systematic Review and Dose Response Meta-analysis Ahmed Almezaine Ministry Of Health Egypt
A-0186 PE1-28 Differences in the risk association of TERT rs2736098 with lung cancer between two ethnic people from different ancestry: A meta-analysis Farhana Sultana Mitu Islamic University Bangladesh
A-0185 PE1-29 A meta-analytic approach to identify the association between p73 rs2273953 to rs1801173 polymorphism and risk of lung cancer Md Abdullah Al Maruf Islamic University Bangladesh
A-0182 PE1-30 SUMOylation-Mediated SHMT2 Degradation by WYC209 Reverses Osimertinib Resistance through Serine-Glycine Pathway Disruption in Lung Cancer Jiaxuan Xu Nanjing University Of Chinese Medicine China
A-0209 PE1-31 CTSC promotes malignant phenotypes and maintains autophagy-related machinery through a YAP-dependent ATG5/ATG7 axis in small cell lung cancer Nayoung Kim Chungnam National University Korea

Big Data & AI

Big Data & AI
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0050 PE1-32 Extended CT Surveillance Beyond 5 Years and Outcomes in Long-term Lung Cancer Survivors Dong Woog Yoon Samsung Medical Center Korea
A-0098 PE1-33 Predicting Lung Cancer Risk Using Machine Learning Models on an Open Clinical Dataset: A Comparative Study Lambe Teddy Pokoknya Ada Medical Research Institute Indonesia
A-0171 PE1-34 Impact of metabolic syndrome on risk of lung cancer among Korean never-smokers: a nationwide population-based cohort study Dongwon Park Shihwa Medical Center Korea
A-0014 PE1-35 Circulating Small Extracellular Vesicle miRNAs as Diagnostic Biomarkers for NSCLC: A Sequencing and Validation Study Kamal Baswal Aiims New Delhi India
A-0086 PE1-36 Automated RECIST-Guided Longitudinal Lesion Tracking on a Per-Timepoint Annotated Thoracic CT Cohort: A Pilot Study Jin Lee Chonnam National University Korea

Others

Others
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0187 PE1-37 Platelet indices as prognostic biomarkers in lung cancer: A meta-analysis Md Abdullah Al Maruf Islamic University Bangladesh
A-0026 PE1-38 A rare case report: Type III Pleuropulmonary Blastoma in a Child with DICER1 Syndrome Chew Way Jin University Malaya Medical Center (PPUM) Malaysia

Pulmonology / Endoscopy

Pulmonology / Endoscopy
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0087 PE1-39 Better Clot Prevention, Greater Bleeding Risk? Optimizing Cancer-Associated Thromboprophylaxis with DOACs Versus LMWH: A Systematic Review and Meta-Analysis Lutfi Hafiz Zunardi Sunan Kalijaga General Hospital Indonesia
A-0154 PE1-40 Intratumoral Cisplatin For Primary And Metastatic Lung Tumors: A Systematic Review Vince Nigel Blanco St. Luke's Medical Center Philippines

Radiology / Staging / Screening / Epidemiology

Radiology / Staging / Screening / Epidemiology
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0200 PE1-41 Discontinuation of Lung Cancer Clinical Studies: A Cross-Sectional Analysis Yousef Radwan Alnomani Faculty Of Medicine, Benha University Egypt
A-0221 PE1-42 Provincial Burden of Lung Cancer Mortality Attributable to Active and Secondhand Smoking Across Indonesia Zulfania Rahmah Al Aziz Hospital Indonesia
A-0220 PE1-43 Three Decades of Lung Cancer DALYs in Southeast Asia: Temporal Trends and Geographic Variation Nazala Safira Universitas Islam Indonesia Indonesia
A-0206 PE1-44 Spatial Distribution of Lung Cancer Disability-Adjusted Life Years and Associated Risk Factors Among Adults Aged 2054 Years in Indonesia Nazala Safira Universitas Islam Indonesia Indonesia
A-0034 PE1-45 Diagnostic Test of an Integrated Immuno-Nutritional Scoring System (INSS) to Differentiate Lung Cancer from Pulmonary Tuberculosis in Resource-Limited Settings Muhamad Ramdani Ibnu Taufik Cakra Husada Hospital Indonesia
A-0052 PE1-46 Clinical And Epidemiologic Profile And Predictors Of Advanced-Stage Disease Among Filipino Female Never-Smokers With Lung Adenocarcinoma: An Analytical Cross-Sectional Study Vince Nigel Blanco St. Luke's Medical Center Philippines
A-0068 PE1-47 Development of a Loop-Mediated Isothermal Amplification Assay for EML4-ALK Variant 1 Detection Ferdinand Mira Ateneo De Manila University Philippines
A-0099 PE1-48 Association Between Household Cooking Fuel Type and Chronic Respiratory Symptoms Among Never-Smoking Indonesian Adults Lambe Teddy Pokoknya Ada Medical Research Institute Indonesia
A-0130 PE1-49 Public Acceptability of Expanding National Lung Cancer Screening Eligibility in South Korea: A Nationwide Survey Jegu Kang National Cancer Center Korea
A-0121 PE1-50 Impact of an Artificial Intelligence Integrated Computer Aided Quality Control System on Screening Accuracy in Korean National Lung Cancer Screening Ji-Youn Song National Cancer Center Korea
A-0119 PE1-51 Participation rates and screening outcomes of the national organized population-based lung cancer screening program in Korea Nayoung Lee National Cancer Center Korea
A-0153 PE1-52 Regional Variations in Young-Onset Lung Cancer Burden Across Java Island: Insights from Five-Year Global Burden of Disease Analysis Cindy Ayudia Pramaesti Kustati Hospital Indonesia
A-0172 PE1-53 Trends in the Burden of Tracheal, Bronchus, and Lung Cancer in Indonesia, 1990 to 2023: Insights From GBD 2023 Adi Nugraha Rsui Banyubening Boyolali Indonesia
A-0198 PE1-54 Development and Validation of a Prognostic Model for Lung Cancer-Specific Survival Following Surgical Resection: A Population-Based study Ahmed Ghait Ministry of Health Egypt
A-0193 PE1-55 Racial and Ethnic Disparities in Surgical Management of Early-Stage Non-Small Cell Lung Cancer: A population based study Ahmed Almezaine Ministry Of Health Egypt
A-0217 PE1-56 Artificial Intelligence for CT-Based Pulmonary Nodule Detection and Lung Cancer Risk Stratification Maha Fatima National Cancer Center Korea
A-0204 PE1-57 Association Between Dietary Inflammatory Index and Lung Cancer Risk: A Systematic Review and Meta-Analysis Amir Hegazi Mansoura University Egypt

Early / Locally Advanced Non-Small Cell Lung Cancer

Early / Locally Advanced Non-Small Cell Lung Cancer
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0008 PE2-01 First-Line Afatinib in Uncommon EGFR-Mutant Stage IV NSCLC: Real-World Outcomes Anh Nguyen Hanoi Medical University Vietnam
A-0037 PE2-02 Clinical Outcomes and Pathological Characteristics of Surgically Resected EGFR-mutant Non-small Cell Lung Cancer According to the Consolidation-to-tumor Ratio: Case-control Study Taehun Kim Keimyung University Dongsan Medical Center Korea
A-0158 PE2-03 Resistance Mechanisms and Secondary Mutations Following Third-Generation EGFR Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-Analysis Nabila Nurisma Faculty Of Medicine Universitas Indonesia Indonesia
A-0162 PE2-04 Chemo-immunotherapy and Surgical Completion in Resectable Non-Small Cell Lung Carcinoma: A TriNetX Study of 11,572 Matched Patients Ahmed Elaraby Faculty Of Medicine, Al-Azhar University Egypt
A-0009 PE2-05 Real-world survival outcomes of afatinib in advanced NSCLC patients with major uncommon EGFR mutations: a subgroup analysis of G719X Anh Nguyen Hanoi Medical University Vietnam
A-0051 PE2-06 Brain Metastases After Lung Adenocarcinoma Surgery: Safer with Neoadjuvant or Adjuvant Chemotherapy? A Nationwide Registry Analysis Nisrina Nabila Universitas Islam Indonesia Indonesia
A-0077 PE2-07 Treatment Preferences for Stage II NSCLC in Korea: A Cross-Sectional Survey on Upfront Surgery versus Neoadjuvant Therapy Jiwon Kwak Samsung Medical Center Korea
A-0085 PE2-08 High Level of Preoperative NK Cell Activity Predicts Delay of Recurrence in Surgically Resected Lung Cancer Seung Hyeun Lee College of Medicine, Kyung Hee University Korea
A-0105 PE2-09 Divergent EMT Regulation in the Tumor-Adjacent Microenvironment Drives Prognostic Divergence in GGO and Solid Lung Adenocarcinoma Han Sanghyun Chungbuk National University College of Medicine Korea
A-0101 PE2-10 Sequential Targeted Therapy and Immunotherapy in NSCLC: A FAERS Analysis Reveals Increased Risk of Severe and Fatal Pneumonitis Ekram Hasanin University Of Tripoli Libyan Arab Jamahiriya

Mesothelioma / Thymic & Other Thoracic Malignancies

Mesothelioma / Thymic & Other Thoracic Malignancies
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0146 PE2-11 Surgical Resection of Residual Mediastinal Masses After Induction Chemotherapy for Primary Mediastinal Non-Seminomatous Germ Cell Tumors Parvin Akhmedov The Loginov Moscow Clinical Scientific Center Russian Federation
A-0156 PE2-12 Integrative Bioinformatic Analysis of Personalized Malignant Suppression with Deoxypodophyllotoxin in Pleural Mesothelioma Patients Anindya Amanda Damayanti Medaeng Public Health Center Indonesia
A-0219 PE2-13 The Only High-Income Country With a Rising Mesothelioma Trend: A Nationwide Prospective Cohort Study From South Korea Kwanyong Hyun The Catholic University of Korea St. Vincent's Hospital Korea
A-0191 PE2-14 Turning Clinical Challenges into Treatment Opportunities: The Role of MDT in Mediastinal Solitary Fibrous Tumour Chan Teng Chong National Cancer Institute, Putrajaya Malaysia

Radiotherapy

Radiotherapy
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0082 PE2-15 Beyond Conventional Dosimetric Indices: A Plan Quality Index Based Evaluation of IMRT, VMAT and Hybrid Plans in NSCLC Shreyasee Karmakar Mgm New Bombay Hospital India
A-0080 PE2-16 Outcomes of Lung Stereotactic Body Radiation Therapy for Pulmonary Metastases from Uncommon Primary Malignancies: An Early Institutional Experience Akshay Mangaj Mpct Hospital India
A-0147 PE2-17 Associations of Chemotherapy and Radiotherapy With Mortality in Lung Cancer: A Population-Based SEER Study Zavia Putri Salsabila Islamic Weleri Hospital Indonesia
A-0038 PE2-18 Optimal Integration of SRS and Next-Generation TKIs for Brain Metastatic in Driver Mutant NSCLC: A Matched Case-Series Keh Yee Tan Sabah Women & Children Hospital Malaysia
A-0199 PE2-19 Prophylactic Cranial Irradiation in the Immunotherapy Era for Extensive-Stage Small Cell Lung Cancer: An Systematic Review and Meta-analysis Mohamed Hegazy Ministry of Health Egypt
A-0184 PE2-20 Association of targeted therapy with outcomes after LINAC-based radiosurgery for lung cancer brain metastases Yen-Ting Liu National Taiwan University Taiwan

Surgery

Surgery
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0023 PE2-21 Surgical Strategy in Patients with Concomitant NonSmall Cell Lung Cancer and Valvular Heart Disease Dam Hai Son E Hospital Vietnam
A-0197 PE2-22 Risk Factors and Mortality Associated with Postoperative Pneumonia Following Lung Cancer Resection: An Systematic Review and Meta-analysis Ahmed Ghait Ministry of Health Egypt

Advanced Non-Small Cell Lung Cancer / Chemotherapy / Targeted Therapy / Immunotherapy

Advanced Non-Small Cell Lung Cancer / Chemotherapy / Targeted Therapy / Immunotherapy
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0027 PE3-01 Osimertinib in Advanced Non-Small Cell Lung Cancer with Uncommon or Compound EGFR Mutations: A retrospective study Trung Nguyen Vietnam National Cancer Hospital Vietnam
A-0032 PE3-02 Beyond Trial Eligibility: Real-World Tolerability and Treatment Persistence of EGFR TKIs in Older Patients With EGFR-Mutated NSCLC Noor Nabila Binti Mohamad National Cancer Institute, Malaysia Malaysia
A-0044 PE3-03 Perioperative Chemotherapy and Mortality Among Surgically Treated Lung Cancer Patients: A SEER Cohort Study Zavia Putri Salsabila Universitas Islam Indonesia Indonesia
A-0043 PE3-04 Treatment Patterns and Temporal Trends in Resectable Clinical Stage II NSCLC: A Single-Center Real-World Analysis Dong Woog Yoon Samsung Medical Center Korea
A-0042 PE3-05 Efficacy and Safety of HER2-Directed Tyrosine Kinase Inhibitors in Advanced HER2-Mutant NonSmall-Cell Lung Cancer: A Meta-Analysis Noha Hammad Faculty Of Medicine, Port Said University Egypt
A-0065 PE3-06 First-Line Pembrolizumab with or without Chemotherapy in Metastatic Non-Small Cell Lung Cancer with Non-EGFR/ALK Driver Mutations: A Real-World Study Minh Truong Vietnam National Cancer Hospital Vietnam
A-0079 PE3-07 STAT5A/B Mediated TH Differentiation and Immune Modulation in Non-Small Cell Lung Cancer Roshni Bibi SRM Institute of Science and Technology India
A-0148 PE3-08 Integrative Bioinformatic Optimization of Personalized Anti-Cancer Drug Targeting Microtubule Depolymerization to Prevent Non-Small Cell Lung Cancer Metastasis Anindya Amanda Damayanti Medaeng Public Health Center Indonesia
A-0145 PE3-09 Conversion Surgery Following Pembrolizumab-Based Chemoimmunotherapy in cT3N2M1 Oligometastatic Non-Small Cell Lung Cancer: Two Cases of Pathologic Complete Response Parvin Akhmedov The Loginov Moscow Clinical Scientific Center Russian Federation
A-0142 PE3-10 Natural Products Targeting the Tumor Immune Microenvironment in Lung Cancer: A Bibliometric Analysis Valentina Aguilera Universitas Palangka Raya Indonesia
A-0138 PE3-11 Systemic Inflammatory Biomarkers Predict Survival Outcomes in Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis Zulfania Rahmah Islamic Indonesia University Indonesia
A-0133 PE3-12 Age Related Molecular Heterogeneity of EGFR Mutated Lung Adenocarcinoma: Differential Distribution of Exon 19 Deletion and L858R Mutations Isura Febrihartati Faculty Of Medicine, University Of Lampung Indonesia
A-0166 PE3-13 Circulating MicroRNAs as Non-Invasive Biomarkers for EGFR-Mutated Lung Adenocarcinoma: A Meta-Analysis Cha Jin Hee University Of Indonesia Indonesia
A-0178 PE3-14 Circulating MicroRNAs Associated with PD-L1 Expression in Non-Small-Cell Lung Cancer: A Systematic Review Cha Jin Hee University Of Indonesia Indonesia
A-0176 PE3-15 Biological Potential Of Engeletin On Apoptotic Cell Death In Lung Cancer Cells And Xenograft Tumors Derived From Cell Lines Dinesh Kumar Patel Sam Higginbottom University Of Agriculture, Technology And Sciences India
A-0218 PE3-16 Sarcopenia as a Prognostic Marker in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Systematic Review and Meta-Analysis. Rashad Mohamed Faculty Of Medicine, Mansoura University Egypt
A-0018 PE3-17 Synchronous Non-Small Cell Lung Cancer with KRAS G12C Mutation and Hepatocellular Carcinoma: A Case Report and Therapeutic Challenges Thao Nguyen Hanoi Medical University Hospital Vietnam
A-0021 PE3-18 KRAS Beyond Boundaries: Unusual Subcutaneous Chest Wall Metastases in KRAS-Mutant Non-Small Cell Lung Cancer - A Five-Case Series Thao Nguyen Hanoi Medical University Hospital Vietnam
A-0031 PE3-19 Predicting the Silent Threat: Risk Stratification for Acute Renal and Hepatic Dysfunction in Lung Cancer Chemotherapy Muhamad Ramdani Ibnu Taufik Cakra Husada Hospital Indonesia
A-0046 PE3-20 Durable Survival Despite Substantial CNS Disease Burden in Metastatic ALK-positive NSCLC: Real-World Outcomes from a Malaysian Cohort. Izzati Rosli National Cancer Institute Putrajaya Malaysia Malaysia
A-0107 PE3-21 Cardiovascular Burden Associated with Immuno-oncology Agents in Lung Cancer: A Systematic Review and Meta-Analysis Elen Putri Cintya Universitas Brawijaya Indonesia
A-0149 PE3-22 Targeting Epithelial-Mesenchymal Transition and Drug Resistance Through YAP1 and AXL Gene Silencing in NSCLC: A Bioinformatics Approach Rian Ka Praja Universitas Palangka Raya Indonesia
A-0139 PE3-23 Unmasking a Rare EGFR Exon 18 Mutation Through Repeat Molecular Profiling in Initially Mutation-Negative Metastatic NSCLC: A Case Report Neshreen Kingking St.luke's Medical Center Philippines
A-0137 PE3-24 Cortisol-ACTH Axis Patterns and Immunotherapy Outcomes in Lung Cancer: A Single-Center Retrospective Cohort Study Da Hyun Kang Chungnam National University Hospital Korea
A-0115 PE3-25 Cycle-to-Cycle ANC Stability Independently Predicts Survival in Heavily Pretreated Advanced NSCLC Receiving Metronomic Weekly Paclitaxel Green Hong Chungnam National University Hospital Korea
A-0170 PE3-26 Real-World Efficacy and Safety of Pemetrexed-Platinum Chemotherapy with or without Bevacizumab in Advanced EGFR-Mutant NSCLC after TKI Failure Vuong Nghiem Tran Danang Oncology Hospital Vietnam
A-0190 PE3-27 Determinants of Therapeutic Response and Survival Outcomes Following EGFR-TKI Therapy in Metastatic EGFR-Mutant NSCLC Jatinkumar Veljibhai Dhanani Gmers Medical College India
A-0225 PE3-28 Efficacy and Safety of Third-Generation EGFR-TKI Combinations versus Monotherapy as First-Line Treatment for EGFR-Mutated Advanced NSCLC: A Bayesian Network Meta-Analysis I Gede Aswin Parisya Sasmana Udayana University Indonesia
A-0214 PE3-29 Second vs Third-Generation EGFR-TKIs as Frontline Treatment for EGFR-Mutant NSCLC: Interim Results from Korean EGFR Registry Seung Hyeun Lee Kyung Hee University Medical Center Korea

Palliative Care

Palliative Care
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0048 PE3-30 Deletion of SASP cardiomyocytes with senolytic drugs conferred therapeutic effects in ICIs-related cardiotoxicity Meng Hou Shanghai Pulmonary Hospital China
A-0062 PE3-31 Emerging Psychotherapy to Support Coping Among Patients with Lung Cancer: A Scoping Review (20202026) Siti Makhmudah Universitas Gadjah Mada Indonesia
A-0136 PE3-32 Digital and Telehealth-Based Palliative Care Interventions for Patients with Advanced Lung Cancer: A Systematic Review of Patient-Centered Outcomes Nazala Safira Universitas Islam Indonesia Indonesia

Small Cell Lung Cancer / Neuroendocrine Tumors

Small Cell Lung Cancer / Neuroendocrine Tumors
Abstract No. Poster No. Abstract Title Presenter Name Affiliation Country
A-0108 PE3-33 Integrated Transcriptomic Identification of Prognostic Neuroendocrine Drivers and Immune Landscape Alterations in Small Cell Lung Cancer Muhammad Hamza Mubarak Universitas Islam Indonesia Pakistan
A-0045 PE3-34 Integrated Transcriptomic Analysis Reveals Neuroendocrine and Cell-Cycle Signatures in Small Cell Lung Cancer Vica Hilda Amelia Universitas Islam Indonesia Indonesia
A-0064 PE3-35 Real-World Pilot Experience of Consolidative Thoracic Radiotherapy with Chemo-Immunotherapy in ES-SCLC: Efficacy and a Key Pulmonary Safety Signal Jae Heun Chung Pusan National University Yangsan Hospital Korea
A-0072 PE3-36 DLL3-based Enrichment Enables Sensitive and Specific Detection of Circulating Tumor Cells During Immunotherapy in Extensive Stage Small-cell Lung Cancer Hyung-Joo Oh Chonnam National University Hwasun Hospital Korea
A-0090 PE3-37 Artificial Intelligence-Based Endothelial Cell Profiling Reveals a Prognostic Signature in the Tumor Microenvironment of Small-Cell Lung Cancer Wonseok Choi Korea University Guro Hospital Korea
A-0095 PE3-38 Clinical Impact and Prognostic Factors of Early Radiotherapy in Limited-Disease Small-Cell Lung Cancer: A Cohort Study Kyung-Il Han Hanyang University Guri Hospital Korea
A-0109 PE3-39 Prophylactic Cranial Irradiation and Survival Outcomes in Treatment Responders with Limited-Stage Small Cell Lung Cancer After Thoracic Radiotherapy Ye Won Kim Keimyung University Dongsan Medical Center Korea
A-0168 PE3-40 The Potential Kemukus (Piper cubeba L.) as Anticancer Agents: An In Silico Study of Activity and and Molecular Interactions Decenly Decenly Universitas Palangka Raya Indonesia
A-0196 PE3-41 Epidemiology and Survival Outcomes of Pulmonary Large Cell Neuroendocrine Carcinoma: A Population-Based Study Abdelrahman Hatata Ministry of Health Egypt